Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice. (August 2017) - Pouwer, Marianne; Pieterman, Elsbet; Verschuren, Lars; Caspers, Martien; Kluft, Kees; Garcia, Ricardo; Lee, Frank; Aman, Jurjan; Jukema, Wouter; Princen, Hans